Obefazimod: the clinical story now meets the filing and funding story
Obefazimod, formerly ABX464, is Abivax's oral investigational compound intended to enhance miR-124 expression.
Obefazimod, formerly ABX464, is Abivax's oral investigational compound intended to enhance miR-124 expression. Its ulcerative-colitis program has moved through induction and maintenance testing. The company reported positive Phase 3 induction findings in 2025 and maintenance findings in June 2026; a planned application is not an approval. Mechanism and program history, maintenance announcement.
ABTECT-1 and ABTECT-2 compared once-daily oral treatment with placebo in moderately to severely active ulcerative colitis. Their principal induction assessment was clinical remission at eight weeks. The separate maintenance record assesses remission at week 44 and retains longer-term safety follow-up. The induction studies are completed in the retrieved records; the maintenance study is active but not recruiting. ABTECT-1, ABTECT-2, maintenance.
Results appearing in a registry in September are a disclosure event, not the first evidence that the studies succeeded. A useful history preserves the earlier company readouts and later registry posting as distinct events. The next disclosed regulatory objective is an application planned by year-end 2026, rather than an application already filed. September 21 update.
Abivax's financing matters because this program is central to a company without the commercial cash-generation base of a large pharmaceutical group. A dated finance entry connects the July offering and management's runway statement to the filing plan. The company account (below) separates June balances, subsequent proceeds and forecast runway. Neither financing nor positive sponsor readouts removes regulatory, manufacturing or longer-term safety uncertainty.
Abivax — company resources
At June 30, Abivax held €388.0 million cash and €14.4 million short-term investments. First-half operating cash use was €102.5 million versus €66.6 million a year earlier; net loss was €165.9 million. The combined borrowings/notes/derivatives line was €1.2 million. July net offering proceeds of €767.1 million are subsequent financing, not June cash. Management's runway forecast extends to Q4 2029. September 21 financial update.
About this account
Published September 23, 2026. Company and regulatory disclosures are covered through September 22; trial-registry records were retrieved September 23. Earlier developments are reconstructed from dated primary sources. Registry status, sponsor-reported results and regulatory decisions are distinguished in the account. Company figures retain their reporting periods; corporate cash is not a compound-specific funding commitment.